MX2014015615A - Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. - Google Patents
Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.Info
- Publication number
- MX2014015615A MX2014015615A MX2014015615A MX2014015615A MX2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A MX 2014015615 A MX2014015615 A MX 2014015615A
- Authority
- MX
- Mexico
- Prior art keywords
- iron
- patients
- reduce
- increase
- ferric citrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662565P | 2012-06-21 | 2012-06-21 | |
| US201361757229P | 2013-01-28 | 2013-01-28 | |
| US201361800618P | 2013-03-15 | 2013-03-15 | |
| US201361801050P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047134 WO2013192565A2 (en) | 2012-06-21 | 2013-06-21 | Use of ferric citrate in the treatment of chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014015615A true MX2014015615A (es) | 2015-03-20 |
Family
ID=49769729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015615A MX2014015615A (es) | 2012-06-21 | 2013-06-21 | Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20130345303A1 (https=) |
| EP (3) | EP2863906B1 (https=) |
| JP (4) | JP2015535209A (https=) |
| KR (2) | KR20200103855A (https=) |
| CN (2) | CN113244209A (https=) |
| AU (2) | AU2013278000A1 (https=) |
| BR (1) | BR112014032049A2 (https=) |
| CA (1) | CA2876982A1 (https=) |
| DK (1) | DK3730136T3 (https=) |
| EA (1) | EA201590062A1 (https=) |
| ES (2) | ES2796254T3 (https=) |
| FR (1) | FR25C1043I1 (https=) |
| HK (1) | HK1214503A1 (https=) |
| IL (1) | IL236356A0 (https=) |
| MX (1) | MX2014015615A (https=) |
| NO (1) | NO2025048I1 (https=) |
| PL (1) | PL3730136T3 (https=) |
| SG (2) | SG11201408521WA (https=) |
| WO (1) | WO2013192565A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011011541A1 (en) | 2009-07-21 | 2011-01-27 | Henry Trong Le | Ferric citrate dosage forms |
| TWI653043B (zh) * | 2012-12-20 | 2019-03-11 | 瑞士商伊蘭科動物健康公司 | 新用途 |
| EP3003327B1 (en) | 2013-06-05 | 2017-08-09 | Tricida Inc. | Proton-binding polymers for oral administration |
| EP2856941B1 (en) * | 2013-10-01 | 2020-11-25 | Fresenius Medical Care Deutschland GmbH | Method and apparatuses for determining a patient's daily loss of iron |
| EP3747432A1 (en) * | 2013-11-04 | 2020-12-09 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
| WO2015110968A1 (en) * | 2014-01-23 | 2015-07-30 | Lupin Limited | Pharmaceutical grade ferric citrate and method for its production |
| EP3157516A4 (en) | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| RS61409B1 (sr) | 2014-12-10 | 2021-03-31 | Tricida Inc | Polimeri koji vezuju protone za oralnu primenu opis |
| TW202302083A (zh) * | 2015-03-04 | 2023-01-16 | 美商凱克斯生物製藥公司 | 檸檬酸鐵用於治療缺鐵性貧血之用途 |
| CN104688706B (zh) * | 2015-04-01 | 2017-07-14 | 成都欣捷高新技术开发有限公司 | 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法 |
| WO2016162794A1 (en) * | 2015-04-08 | 2016-10-13 | Leiutis Pharmaceuticals Pvt Ltd | Pharmaceutical compositions of ferric citrate |
| WO2016162888A1 (en) * | 2015-04-09 | 2016-10-13 | Actavis Group Ptc Ehf. | Process for preparing pharmaceutical grade ferric citrate |
| CN109414453B (zh) | 2016-05-06 | 2023-02-17 | 特里赛达公司 | 用于治疗酸碱失衡的组合物 |
| WO2019059172A1 (ja) | 2017-09-19 | 2019-03-28 | 日本たばこ産業株式会社 | 過多月経患者及び／又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び／又は治療におけるクエン酸第二鉄の使用 |
| CA3080651A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| MX2021004640A (es) | 2018-10-29 | 2021-05-28 | Pharmacosmos Holding As | Tratamiento de la deficiencia de hierro con carboximaltosa ferrica. |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| EP4347022A1 (en) | 2021-05-27 | 2024-04-10 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN115024495B (zh) * | 2022-06-27 | 2024-03-22 | 北京金康普食品科技有限公司 | 改善肾病患者钙磷代谢的营养组合物及其应用 |
| WO2025181559A1 (en) * | 2024-02-29 | 2025-09-04 | Sloiron, Inc. | Methods for determining the amount of encapsulated and free iron in a sample |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1230118A (zh) * | 1996-07-19 | 1999-09-29 | 日研化学株式会社 | 高磷血症治疗剂 |
| US5753706A (en) * | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| US8093423B2 (en) | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| CN1600302A (zh) * | 2003-09-22 | 2005-03-30 | 宝龄富锦生技股份有限公司 | 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品 |
| US20060134227A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Compositions including iron |
| CA2619591C (en) | 2005-08-18 | 2020-03-24 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| PT1973549T (pt) * | 2006-01-06 | 2016-10-25 | Luitpold Pharm Inc | Métodos e composições para administração de ferro |
| JP2009525277A (ja) * | 2006-01-30 | 2009-07-09 | グロボアジア エルエルシー | 軟組織石灰化の回復、予防、遅延または安定化方法 |
| WO2011011541A1 (en) | 2009-07-21 | 2011-01-27 | Henry Trong Le | Ferric citrate dosage forms |
-
2013
- 2013-06-21 US US13/924,332 patent/US20130345303A1/en not_active Abandoned
- 2013-06-21 CN CN202110644193.4A patent/CN113244209A/zh active Pending
- 2013-06-21 AU AU2013278000A patent/AU2013278000A1/en not_active Abandoned
- 2013-06-21 ES ES13807102T patent/ES2796254T3/es active Active
- 2013-06-21 EP EP13807102.2A patent/EP2863906B1/en active Active
- 2013-06-21 KR KR1020207024260A patent/KR20200103855A/ko not_active Ceased
- 2013-06-21 KR KR1020157001458A patent/KR102150135B1/ko active Active
- 2013-06-21 SG SG11201408521WA patent/SG11201408521WA/en unknown
- 2013-06-21 CN CN201380044271.0A patent/CN104884055A/zh active Pending
- 2013-06-21 BR BR112014032049A patent/BR112014032049A2/pt not_active IP Right Cessation
- 2013-06-21 EP EP23219273.2A patent/EP4335436A3/en not_active Withdrawn
- 2013-06-21 ES ES20163104T patent/ES2970050T3/es active Active
- 2013-06-21 EA EA201590062A patent/EA201590062A1/ru unknown
- 2013-06-21 SG SG10201805177PA patent/SG10201805177PA/en unknown
- 2013-06-21 CA CA2876982A patent/CA2876982A1/en not_active Abandoned
- 2013-06-21 PL PL20163104.1T patent/PL3730136T3/pl unknown
- 2013-06-21 EP EP20163104.1A patent/EP3730136B1/en active Active
- 2013-06-21 MX MX2014015615A patent/MX2014015615A/es unknown
- 2013-06-21 DK DK20163104.1T patent/DK3730136T3/da active
- 2013-06-21 WO PCT/US2013/047134 patent/WO2013192565A2/en not_active Ceased
- 2013-06-21 HK HK16102352.0A patent/HK1214503A1/zh unknown
- 2013-06-21 JP JP2015518623A patent/JP2015535209A/ja active Pending
-
2014
- 2014-04-25 US US14/262,465 patent/US20140234416A1/en not_active Abandoned
- 2014-10-24 US US14/523,656 patent/US20150079168A1/en not_active Abandoned
- 2014-12-18 IL IL236356A patent/IL236356A0/en unknown
-
2018
- 2018-04-10 JP JP2018075243A patent/JP2018138562A/ja active Pending
- 2018-05-08 AU AU2018203205A patent/AU2018203205B2/en not_active Ceased
-
2020
- 2020-02-25 JP JP2020029756A patent/JP2020100638A/ja active Pending
-
2022
- 2022-02-10 JP JP2022019167A patent/JP2022070945A/ja active Pending
-
2025
- 2025-11-06 NO NO2025048C patent/NO2025048I1/no unknown
- 2025-11-18 FR FR25C1043C patent/FR25C1043I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014015615A (es) | Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica. | |
| MX2016005734A (es) | Citrato férrico para reducir falla cardíaca en pacientes con enfermedad renal crónica. | |
| AR061170A1 (es) | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) | |
| JOP20180104B1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
| EA201591427A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| MY183637A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| BR112012033044A2 (pt) | composição de precursor de diálise | |
| MY191087A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| EA201591426A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| NZ702469A (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| EA201591424A1 (ru) | Способы лечения дефицита железа растворимым пирофосфатом железа | |
| WO2010119991A3 (en) | Anti-hgf antibody combinational cancer therapies | |
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| BR112014009414A2 (pt) | uso de micelas de proteína de soro do leite para melhorar o perfil de insulina em pacientes diabéti-cos | |
| EA201500232A1 (ru) | Три(гетеро)арилпиразолы и их применение | |
| RU2014145887A (ru) | Комбинированная терапия с использованием антител против mif и химиотерапевтических средств | |
| EA201891922A1 (ru) | Лекарственное средство для лечения инфекций на фоне диабетической стопы | |
| NZ725920A (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| YANG et al. | Status of proteasome inhibitors in the treatment of multiple myeloma | |
| Al-Hashimi et al. | Binding of anti-GRP78 autoantibodies to cell surface GRP78 promotes cancer progression by activating tissue factor procoagulant activity | |
| RU2013110191A (ru) | Способ определения предикторной значимости мозгового натрийуретического пептида у больных хронической болезнью почек, получающих терапию программным гемодиализом |